Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035529 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00035529 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb.
The verdict
NCT00035529, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
Interventions
- DRUG Placebo
- DRUG BMS 188667 (Abatacept)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-11 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035529
The ClinicalTrials.gov registry entry for NCT00035529 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00035529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035529 about?
NCT00035529 is a clinical study titled "A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis". The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
What is the current status of trial NCT00035529?
This trial is currently terminated. It is a Phase 2 study. The study started on 2001-11. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00035529?
The interventions under investigation include: Placebo (DRUG), BMS 188667 (Abatacept) (DRUG).
Who is sponsoring clinical trial NCT00035529?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.